Display options
Cite
Rojas M, Rodríguez Y, Ramírez-Santana C, et al. Impact of hyperprolactinemia in a patient with polyautoimmunity. Clin Case Rep. 2018;7(1):19-23doi: 10.1002/ccr3.1900.
Rojas, M., Rodríguez, Y., Ramírez-Santana, C., & Anaya, J. M. (2019). Impact of hyperprolactinemia in a patient with polyautoimmunity. Clinical case reports, 7(1), 19-23. https://doi.org/10.1002/ccr3.1900
Rojas, Manuel, et al. "Impact of hyperprolactinemia in a patient with polyautoimmunity." Clinical case reports vol. 7,1 (2019): 19-23. doi: https://doi.org/10.1002/ccr3.1900
Rojas M, Rodríguez Y, Ramírez-Santana C, Anaya JM. Impact of hyperprolactinemia in a patient with polyautoimmunity. Clin Case Rep. 2018 Nov 09;7(1):19-23. doi: 10.1002/ccr3.1900. eCollection 2019 Jan. PMID: 30656000; PMCID: PMC6333117.
Copy Download .nbib Format: NLM
Share it on

Clin Case Rep. 2018 Nov 09;7(1):19-23. doi: 10.1002/ccr3.1900. eCollection 2019 Jan.

Impact of hyperprolactinemia in a patient with polyautoimmunity.

Clinical case reports

Manuel Rojas, Yhojan Rodríguez, Carolina Ramírez-Santana, Juan-Manuel Anaya

Affiliations

  1. Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences Universidad del Rosario Bogota Colombia.
  2. Doctoral Program in Biomedical Sciences Universidad del Rosario Bogotá Colombia.

PMID: 30656000 PMCID: PMC6333117 DOI: 10.1002/ccr3.1900

Abstract

Hyperprolactinemia has been proposed as a triggering factor for autoimmune diseases. The increased levels of prolactin could induce an abnormal immune response. Herein, we present a patient with hyperprolactinemia who developed polyautoimmunity. Patient's symptoms were associated with slightly raised levels of prolactin (20-40 ng/mL) and administration of dopaminergic agonists.

Keywords: Sjögren's syndrome; hyperprolactinemia; prolactin; systemic lupus erythematosus

References

  1. Ann Rheum Dis. 2001 Mar;60(3):242-7 - PubMed
  2. Isr Med Assoc J. 2005 Nov;7(11):740-1 - PubMed
  3. Clin Rheumatol. 2006 Jul;25(4):602-5 - PubMed
  4. Biochem Biophys Res Commun. 2008 Aug 22;373(2):286-91 - PubMed
  5. Expert Rev Clin Immunol. 2007 Jul;3(4):623-35 - PubMed
  6. J Immunol. 2011 Mar 15;186(6):3745-52 - PubMed
  7. Exp Mol Pathol. 2011 Oct;91(2):548-62 - PubMed
  8. Autoimmun Rev. 2012 May;11(6-7):A465-70 - PubMed
  9. PLoS One. 2012;7(1):e29819 - PubMed
  10. Iran Red Crescent Med J. 2011 Oct;13(10):749-50 - PubMed
  11. Endocr Rev. 2013 Apr;34(2):239-77 - PubMed
  12. BMC Med. 2013 Mar 18;11:73 - PubMed
  13. Pharmacol Ther. 2014 Feb;141(2):125-39 - PubMed
  14. Int J Mol Sci. 2014 Jun 05;15(6):10116-35 - PubMed
  15. J Immunol Res. 2014;2014:385352 - PubMed
  16. Autoimmun Rev. 2015 Mar;14(3):223-30 - PubMed
  17. Cytokine. 2015 Dec;76(2):280-287 - PubMed
  18. Pituitary. 2016 Apr;19(2):202-9 - PubMed
  19. Arthritis Rheumatol. 2016 May;68(5):1124-35 - PubMed
  20. Eur J Endocrinol. 2016 Jul;175(1):63-72 - PubMed
  21. Immunol Res. 2017 Apr;65(2):512-523 - PubMed
  22. World Neurosurg. 2017 Apr;100:407-416 - PubMed
  23. JAMA. 2017 Feb 7;317(5):516-524 - PubMed
  24. Front Immunol. 2018 Feb 12;9:73 - PubMed
  25. Autoimmun Rev. 2018 Jul;17(7):709-714 - PubMed
  26. Br Med J. 1979 Sep 22;2(6192):700-3 - PubMed
  27. Arthritis Rheum. 1997 Aug;40(8):1383-6 - PubMed

Publication Types